1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidine-7-one
M&B22948 White solid. A cell-permeable, selective inhibitor of cGMP-specific phosphodiesterase (PDE V; IC50 = 450 nM). Inhibits PDE IX at higher concentration (IC50 = 35 µM). Also known to increase cGMP levels in spontaneously hypertensive rat (SHR) plasma and reverse nitroglycerin tolerance in vitro. Enhances the vasodilatory effects of nitric oxide. Purity: ≥98% by TLC. CAS 37762-06-4. Ref.: Fisher, D.A., et al. 1998. J. Biol. Chem. 273, 15559. Tsusu, K.G., et al. 1995. Am. J. Respir. Crit. Care Med. 152, 1605. Dundore, R.L., et al. 1993. Eur. J. Pharmacol. 249, 293. Pagani, E.D., et al. 1993. Eur. J. Pharmacol. 243, 141. Burns, F., et al. 1992. Biochem. J. 283, 487. Lugnier, C., et al. 1992. Am. J. Physiol. 262, H654.
R: 36/37/38; S: 26-36 |
